TNSN99135A1 - Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression - Google Patents
Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depressionInfo
- Publication number
- TNSN99135A1 TNSN99135A1 TNTNSN99135A TNSN99135A TNSN99135A1 TN SN99135 A1 TNSN99135 A1 TN SN99135A1 TN TNSN99135 A TNTNSN99135 A TN TNSN99135A TN SN99135 A TNSN99135 A TN SN99135A TN SN99135 A1 TNSN99135 A1 TN SN99135A1
- Authority
- TN
- Tunisia
- Prior art keywords
- anxiety
- depression
- prevention
- nervous
- treatment
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000003542 behavioural effect Effects 0.000 title 1
- 230000000324 neuroprotective effect Effects 0.000 title 1
- 235000005911 diet Nutrition 0.000 abstract 2
- 230000000378 dietary effect Effects 0.000 abstract 2
- YDOIFHVUBCIUHF-UHFFFAOYSA-N 9,11,13,16,18,20-hexahydroxy-5,24-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione Chemical compound OC1=CC(O)=C2C(O)=C3C(=O)C=C(C)C4=C5C(C)=CC(=O)C6=C(O)C7=C(O)C=C(O)C8=C7C(=C56)C(=C34)C2=C18 YDOIFHVUBCIUHF-UHFFFAOYSA-N 0.000 abstract 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229940005608 hypericin Drugs 0.000 abstract 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 abstract 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
-UNE COMPOSITION EST I133DIVULGUEE ET H130EST DESTINEE A LA PREVENTION ET/OU AU TRAITEMENT THERAPEUTIQUE DES TROUBLES NERVEUX ET DE COMPORTEMENTS DUS AUX ETATS D'ANXIETE OU DE DEPRESSION, ET QUI PEUT PRENDRE LA FORME D'UN SUPPLEMENT DIETETIQUE, D'UN SUPPORT DIETETIQUE OU D'UN MEDICAMENT EFFECTIF, ET QUI COMPREND COMME INGREDIENTS ACTIFS CARACTERISTIQUES L'ACETYL L-CARNITINE ET L'HYPERICINE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98RM000425A IT1299195B1 (it) | 1998-06-25 | 1998-06-25 | Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN99135A1 true TNSN99135A1 (fr) | 2005-11-10 |
Family
ID=11406010
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN99135A TNSN99135A1 (fr) | 1998-06-25 | 1999-06-25 | Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6346282B1 (fr) |
| EP (1) | EP1089744B1 (fr) |
| JP (1) | JP2002518438A (fr) |
| KR (1) | KR20010053059A (fr) |
| CN (1) | CN1307479A (fr) |
| AT (1) | ATE228369T1 (fr) |
| AU (1) | AU756542B2 (fr) |
| BR (1) | BR9912179A (fr) |
| CA (1) | CA2334858C (fr) |
| DE (1) | DE69904173T2 (fr) |
| DK (1) | DK1089744T3 (fr) |
| EE (1) | EE200000729A (fr) |
| ES (1) | ES2188178T3 (fr) |
| HU (1) | HUP0102546A3 (fr) |
| IL (1) | IL140159A0 (fr) |
| IS (1) | IS5765A (fr) |
| IT (1) | IT1299195B1 (fr) |
| MA (1) | MA26651A1 (fr) |
| NO (1) | NO20006430L (fr) |
| NZ (1) | NZ508882A (fr) |
| PL (1) | PL194177B1 (fr) |
| PT (1) | PT1089744E (fr) |
| SK (1) | SK19302000A3 (fr) |
| TN (1) | TNSN99135A1 (fr) |
| TR (1) | TR200003736T2 (fr) |
| WO (1) | WO1999066914A2 (fr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6348495B1 (en) * | 1996-06-06 | 2002-02-19 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Method for treating celiac disease |
| DE10015617A1 (de) * | 2000-03-29 | 2001-10-04 | Peter Laetzsch | Migränemittel |
| US7208180B2 (en) * | 2000-05-08 | 2007-04-24 | N.V. Nutricia | Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith |
| US7226916B1 (en) | 2000-05-08 | 2007-06-05 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
| IT1317035B1 (it) * | 2000-05-30 | 2003-05-26 | Sigma Tau Healthscience Spa | Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal |
| US7407778B2 (en) * | 2002-02-07 | 2008-08-05 | Pettegrew Jay W | Compounds, compositions and methods for treating neuropsychiatric disorders |
| US7700074B2 (en) * | 2002-02-07 | 2010-04-20 | Pettegrew Jay W | Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism |
| DE10213571A1 (de) * | 2002-03-26 | 2003-10-23 | Lichtwer Pharma Ag | Pflanzenextrakte und deren Anwendung |
| US7674482B2 (en) * | 2002-08-27 | 2010-03-09 | Targeted Medical Pharma Inc. | Method and compositions for potentiating pharmaceuticals with amino acid based medical foods |
| US20040067986A1 (en) * | 2002-10-04 | 2004-04-08 | Nathan Sassover | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer |
| WO2004110963A2 (fr) * | 2003-05-29 | 2004-12-23 | Pettegrew Jay W | Composes, compositions et procedes d'imagerie medicale permettant d'obtenir des image de troubles neuropsychiatriques |
| US20060257842A1 (en) * | 2003-05-29 | 2006-11-16 | Pettegrew Jay W | Cryopreservation media and molecules |
| US20050232911A1 (en) * | 2004-04-19 | 2005-10-20 | Schreiber Brian D | Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid |
| US20070065486A1 (en) * | 2004-05-21 | 2007-03-22 | Migco Limited | Migraine remedy |
| US20060115556A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplement drink containing xanthone extracts |
| US20060115555A1 (en) * | 2004-12-01 | 2006-06-01 | Foulger Sidney W | Nutritional supplements containing xanthone extracts |
| EP1854486A3 (fr) * | 2006-03-14 | 2010-06-02 | Wilfried P. Bieger | Utilisation de dérivés de neurotransmetteurs destinée à la fabrication d'agents de traitement des perturbations neuroendocrines liées à la santé |
| WO2009128057A2 (fr) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Produits psycho-pharmaceutiques |
| JP2012508267A (ja) * | 2008-11-11 | 2012-04-05 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | セルライトの処置に有用な化合物 |
| BRPI0900614A2 (pt) | 2009-02-13 | 2011-06-28 | Univ Fed Do Rio Grande Do Sul Ufrgs | extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção |
| EP2582368B1 (fr) * | 2010-06-16 | 2018-05-09 | Alfasigma S.p.A. | Acetyl-Lcarnitine pour augmenter la neurogénèse dans le tissu neuronal |
| ES2575995T3 (es) | 2010-08-05 | 2016-07-04 | Case Western Reserve University | Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal |
| JP2014145857A (ja) | 2013-01-28 | 2014-08-14 | Sony Corp | 表示装置およびその製造方法、並びに電子機器 |
| WO2016126169A1 (fr) * | 2015-02-04 | 2016-08-11 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Procédé pour augmenter l'efficacité de la thérapie par antidépresseurs dans le cadre d'une thérapie anti-dépression et combinaison pharmaceutique |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346107A (en) * | 1979-02-12 | 1982-08-24 | Claudio Cavazza | Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism |
| DE4239959A1 (de) * | 1992-11-27 | 1994-06-01 | Schwabe Willmar Gmbh & Co | Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung |
| IT1276225B1 (it) * | 1995-10-17 | 1997-10-27 | Sigma Tau Ind Farmaceuti | Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per |
| US5911992A (en) * | 1997-06-12 | 1999-06-15 | A. Glenn Braswell | Method for controlling weight with hypericum perforatum and garcinia cambogia |
-
1998
- 1998-06-25 IT IT98RM000425A patent/IT1299195B1/it active IP Right Grant
-
1999
- 1999-06-15 MA MA25627A patent/MA26651A1/fr unknown
- 1999-06-17 ES ES99926750T patent/ES2188178T3/es not_active Expired - Lifetime
- 1999-06-17 AU AU43910/99A patent/AU756542B2/en not_active Ceased
- 1999-06-17 TR TR2000/03736T patent/TR200003736T2/xx unknown
- 1999-06-17 NZ NZ508882A patent/NZ508882A/en unknown
- 1999-06-17 US US09/719,551 patent/US6346282B1/en not_active Expired - Fee Related
- 1999-06-17 DE DE69904173T patent/DE69904173T2/de not_active Expired - Lifetime
- 1999-06-17 IL IL14015999A patent/IL140159A0/xx unknown
- 1999-06-17 HU HU0102546A patent/HUP0102546A3/hu unknown
- 1999-06-17 EP EP99926750A patent/EP1089744B1/fr not_active Expired - Lifetime
- 1999-06-17 KR KR1020007014521A patent/KR20010053059A/ko not_active Withdrawn
- 1999-06-17 CN CN99807870A patent/CN1307479A/zh active Pending
- 1999-06-17 WO PCT/IT1999/000175 patent/WO1999066914A2/fr not_active Application Discontinuation
- 1999-06-17 PT PT99926750T patent/PT1089744E/pt unknown
- 1999-06-17 JP JP2000555600A patent/JP2002518438A/ja active Pending
- 1999-06-17 CA CA2334858A patent/CA2334858C/fr not_active Expired - Fee Related
- 1999-06-17 AT AT99926750T patent/ATE228369T1/de active
- 1999-06-17 SK SK1930-2000A patent/SK19302000A3/sk unknown
- 1999-06-17 EE EEP200000729A patent/EE200000729A/xx unknown
- 1999-06-17 PL PL99345279A patent/PL194177B1/pl not_active IP Right Cessation
- 1999-06-17 DK DK99926750T patent/DK1089744T3/da active
- 1999-06-17 BR BR9912179-4A patent/BR9912179A/pt not_active IP Right Cessation
- 1999-06-25 TN TNTNSN99135A patent/TNSN99135A1/fr unknown
-
2000
- 2000-12-08 IS IS5765A patent/IS5765A/is unknown
- 2000-12-15 NO NO20006430A patent/NO20006430L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN99135A1 (fr) | Composition neuroprotectrice pour la prevention et/ou le traitement des troubles nerveux ou de comportement dus aux etats d'anxiete ou de depression | |
| TNSN99132A1 (fr) | Une composition pour la prevention et/ou le traitement de l'osteoporose ou des alterations dues au syndrome de menopause | |
| TNSN99163A1 (fr) | COMPOSITION ANTIOXYDANTE COMPRENANT L'ACETYL-CARNITINE ET L'ACIDE α -LIPOIQUE QUI AMELIORE L'UTILISATION METABOLIQUE DU GLUCOSE | |
| PL364174A1 (en) | Fibrate-statin combinations with reduced fed-fasted effects | |
| TNSN95046A1 (fr) | Formes posologiques d'azithromycine pour le traitement d'infections microbiennes | |
| PT918517E (pt) | Composicao de microrganismos contendo acidos gordos omega-3 util como agente profilactico ou terapeutico contra a cocidiose dos animais | |
| TNSN04191A1 (fr) | Composes qui modulent l'activite de ppar et procedes pour leur preparation | |
| FR2751878B1 (fr) | Utilisation dans une composition d'un extrait d'au moins une labiee | |
| MA27863A1 (fr) | Forme posologique à libération prolongée d'anesthésiques pour le traitement de la douleur | |
| TNSN99186A1 (fr) | Utilisation des carnitines et du resveratrol pour produire une composition pour la prevention ou le traitement therapeutique des troubles cerebraux dus au vieillissements et a l'utilisation des substances neurotoxiques | |
| PT920323E (pt) | Nova utilizacao de fosfolipidos de origem animal em terapeutica e/ou dietetica | |
| CA2150184A1 (fr) | Composition pharmaceutique pour le traitement des affections intestinales inflammatoires | |
| EP0699439A3 (fr) | Traitement des maladies provoquées par des troubles des glandes sébacés avec l'emploi d'inhibiteurs de l'acyl CoA cholestérol acyl transferase | |
| BR9607541A (pt) | Tratamento de doenças que tem por causa o fator de crescimento da citoquina | |
| BR9809678A (pt) | Derivados de triptolìdeo úteis no tratamento de doenças autoimunes | |
| WO1997022354A3 (fr) | Emploi d'un medicament et utilisation d'un melange de substances pour la production d'un medicament | |
| FR2712495B1 (fr) | Application de l'Óoenotheine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, et les compositions pharmaceutiques le contenant. | |
| TNSN99138A1 (fr) | Une composition antioxydante, cytostatique et a support energetique qui ameliore l'utilisation metabolique du glucose | |
| DZ2564A1 (fr) | Compositions pharmaceutiques pour le traitement dudiabète sucre et d'états associés. | |
| FR2619713B1 (fr) | Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression | |
| TNSN00216A1 (fr) | Une composition pour la prevention et/ou pour le traitement des troubles dus aux anomalies du metabolisme des lipides, comportant la propionyl l-carnitine et le chitosane | |
| BR0015781A (pt) | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea | |
| KR930021178A (ko) | 뼈 형성을 자극하는 약제 | |
| EP0820771A3 (fr) | Composition pharmaceutique pour le traitement de neuropathies contenant une thiamine liposoluble et un composé de magnésium | |
| FI953622L (fi) | Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon |